Concepedia

Paul M. Bennett

PM

Statistics

Publications

4

Citations

176

H-Index

4

Active since

2015

Affiliations

Novartis (United States)(Current)

Brigham and Women's Hospital

Harvard University

Paul M. Bennett is an author at Novartis (United States) specializing in life sciences, immunology, and signal transduction.

Publications per year

2015–2021

4

Publications

4

The cerebral cavernous malformation proteins CCM2L and CCM2 prevent the activation of the MAP kinase MEKK3

Xavier Culleré, Eva Plovie, Paul M. Bennett et al. · Proceedings of the National Academy of Sciences · 2015 · 74 citations · Full text

, , +14

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma

Dexiu Bu, Reshma Singh, Eugene Choi et al. · Oncotarget · 2018 · 71 citations · Full text

, , +17

AKAP9 regulates activation-induced retention of T lymphocytes at sites of inflammation

Jan M. Herter, Nir Grabie, Xavier Culleré et al. · Nature Communications · 2015 · 20 citations · Full text

, , +16

Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured with a Novel T-Charge TM Platform for the Treatment of Multiple Myeloma

Dexiu Bu, Paul M. Bennett, Nathaniel Barton et al. · Blood · 2021 · 11 citations

, , +16

1–4 of 4